The impact of the above structural modifications on the respective [111In]In-radioligands was assessed in a series of in vitro and animal assays, based on GRPR-expressing human cancer cells, to reveal the most promising candidate for further evaluation after labeling with Lu-177. The gene discussed is GRPR; the disease is cancer.